Arbovirus Testing Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (RT-PCR Test, ELISA-Test), By End User (Hospitals, Diagnostic Centers), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.07 Billion
CAGR (2026-2031)	5.91%
Fastest Growing Segment	ELISA-Test
Largest Market	North America
Market Size (2031)	USD 2.92 Billion

Market Overview

The Global Arbovirus Testing Market will grow from USD 2.07 Billion in 2025 to USD 2.92 Billion by 2031 at a 5.91% CAGR. The Global Arbovirus Testing Market comprises diagnostic assays and reagents, including ELISA and RT-PCR kits, utilized to detect infections transmitted by arthropod vectors such as mosquitoes and ticks. The primary driver for this market is the escalating prevalence of vector-borne diseases like Dengue, Zika, and Chikungunya, exacerbated by climate change and rapid urbanization which expand vector habitats. Additionally, increased government funding for public health surveillance and the implementation of early warning systems to manage outbreaks significantly bolster the demand for rapid and accurate diagnostic solutions.

A major challenge hindering market expansion is the cross-reactivity of antibodies in serological tests, which often leads to false positives and complicates diagnosis in regions where multiple arboviruses co-circulate. This technical limitation underscores the urgent need for highly specific diagnostic tools to differentiate between closely related viruses. According to the 'European Centre for Disease Prevention and Control', in '2024', 'over 14 million dengue cases and over 10,000 dengue-related deaths were reported globally', highlighting the immense disease burden that necessitates robust and scalable testing infrastructures.

Key Market Drivers

The Rising Global Prevalence of Arboviral Infections serves as a primary catalyst for the market, driven by the expansion of mosquito habitats and climate change which facilitate the spread of pathogens to new regions. This escalating disease burden creates an urgent necessity for diagnostic assays capable of detecting and differentiating emerging threats beyond traditional outbreaks. For instance, according to the Pan American Health Organization, December 2024, in the 'Americas report record dengue and Oropouche cases' update, there were 11,600 Oropouche cases recorded in the region in 2024, a significant increase from just 832 cases in 2023. Such exponential growth in infection rates compels healthcare authorities to procure advanced testing kits to manage the complex epidemiological landscape, thereby directly increasing the volume of diagnostic products utilized globally.

Increasing Government Funding for Public Health Surveillance acts as the second major driver, providing the financial backbone for the modernization of laboratory infrastructures and vector control programs. Federal and international bodies are allocating substantial resources to ensure laboratories are equipped with the necessary tools to monitor and respond to outbreaks effectively. According to the American Association of Veterinary Medical Colleges, April 2025, appropriations for the CDC's Division of Vector-Borne Diseases reached $90.6 million for the 2025 fiscal year to support surveillance and prevention efforts. This financial commitment is mirrored on a global scale to enhance testing capacity; according to the International Atomic Energy Agency, October 2025, in the 'Annual Report 2024', the ZODIAC initiative equipped nearly 40 veterinary laboratories with diagnostic tools to combat zoonotic outbreaks. This influx of capital directly translates into sustained demand for molecular and serological testing solutions.

Download Free Sample Report

Key Market Challenges

Cross-reactivity inherent in serological diagnostic tools presents a substantial impediment to the commercial progress of the arbovirus testing sector. This limitation arises when assays fail to accurately differentiate between antibodies of structurally similar viruses, leading to a high frequency of false-positive results. Such inaccuracies erode end-user confidence and necessitate additional confirmatory testing, which raises overall healthcare expenditures and extends diagnostic turnaround times. Consequently, adoption rates for rapid serological kits struggle to gain momentum in regions where specific diagnosis is critical for patient safety.

The magnitude of this issue is underscored by the sheer volume of cases requiring differentiation. According to the 'Pan American Health Organization', in '2024', 'the Region of the Americas reported more than 11 million suspected cases of dengue'. In environments with such heavy disease burdens, the inability of standard tests to distinguish dengue from other co-circulating arboviruses creates operational bottlenecks. This lack of specificity limits the scalability of current testing products and restricts revenue potential in high-demand geographical territories.

Key Market Trends

The Implementation of Automated High-Throughput Laboratory Systems is fundamentally transforming the Global Arbovirus Testing Market by enabling clinical laboratories to manage the surging volume of diagnostic requests during peak outbreak seasons. As transmission intensifies, diagnostic manufacturers are prioritizing the development of fully automated immunoassays that streamline workflows and ensure rapid turnaround times, a critical factor for effective patient management. This shift toward high-capacity infrastructure is exemplified by recent regulatory approvals for systems designed to process massive sample volumes with minimal human intervention. According to Roche, October 2025, in the 'Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue' press release, the company secured certification for a new automated antigen test capable of delivering results in just 18 minutes, significantly enhancing laboratory efficiency in high-demand regions.

Simultaneously, the Development of Advanced Microfluidic and Biosensor Platforms is addressing the critical industry challenge of serological cross-reactivity. Innovations in this space focus on utilizing novel microsphere technologies and biosensing interfaces to achieve precise differentiation between structurally similar flaviviruses, such as Zika and Dengue, which traditional assays often fail to distinguish. These sophisticated platforms offer higher specificity, reducing the clinical burden of false-positive results and facilitating more accurate epidemiological surveillance. For instance, according to the University of North Carolina at Chapel Hill, February 2025, in the 'New Assay Promises Accurate Diagnosis and Surveillance of Dengue and Zika Viruses' article, researchers designed a multiplex microsphere assay that achieved 94.9% sensitivity in detecting past dengue infections while effectively differentiating them from Zika antibodies.

Segmental Insights

The ELISA-Test segment is identified as the fastest-growing category within the Global Arbovirus Testing Market, driven by its critical role in mass surveillance and large-scale population screening. This serological method is increasingly prioritized for its cost-effectiveness and scalability, particularly in high-prevalence regions where resource constraints limit the widespread use of complex molecular alternatives. Furthermore, the assay’s high sensitivity in detecting specific antibodies aligns with standard diagnostic protocols for confirming recent infections. Consequently, healthcare systems are rapidly adopting these adaptable tests to strengthen outbreak monitoring and ensure efficient disease management globally.

Regional Insights

North America holds a dominant position in the Global Arbovirus Testing Market, primarily driven by its highly developed healthcare infrastructure and substantial healthcare expenditure. The region proactively manages the rising incidence of vector-borne diseases, such as West Nile virus and Dengue, through robust government surveillance programs. Furthermore, the presence of major diagnostic manufacturers in the United States fosters continuous innovation in molecular diagnostics and rapid testing solutions. Strict regulatory standards enforced by bodies like the U.S. Food and Drug Administration (FDA) ensure high-quality diagnostic protocols, further solidifying the region’s market leadership.

Recent Developments

• In October 2025, Roche received the CE mark for its Elecsys Dengue Ag test, a fully automated immunoassay intended for the diagnosis of acute dengue infection. This regulatory approval allowed the company to market the high-throughput diagnostic tool in countries recognizing the certification. The test was engineered to detect the dengue NS1 antigen in human serum and plasma, providing laboratories with an efficient solution to manage large testing volumes during outbreaks. By automating the detection process, the company aimed to enhance laboratory workflow efficiency and support faster clinical decision-making for patients suspected of having the virus.
• In August 2025, Anbio Biotechnology expanded its portfolio of infectious disease diagnostics with the commercial launch of a rapid test for Chikungunya fever. The new Chikungunya IgM/IgG Rapid Test was developed to provide clinicians and public health authorities with a fast and accessible tool for detecting specific antibodies in human blood samples. This product launch was intended to support global efforts in managing outbreaks by facilitating the timely differentiation of Chikungunya from other arboviruses with overlapping clinical presentations. The test employed immunochromatographic technology to deliver qualitative results, making it suitable for point-of-care settings.
• In July 2025, Quest Diagnostics introduced a new molecular laboratory test designed to aid in the detection of the Oropouche virus. This development was a direct response to the increasing prevalence of the virus in parts of South and Central America and the Caribbean, as well as emerging cases in other regions. The test, which utilizes polymerase chain reaction technology, was made available to healthcare providers to assist in the accurate diagnosis of patients presenting with symptoms similar to other arboviral diseases. This launch highlighted the company's commitment to responding to emerging infectious disease threats with advanced diagnostic capabilities.
• In April 2024, Grifols secured the CE mark under the In Vitro Diagnostic Regulation for its new molecular diagnostic assay designed to detect multiple arboviruses. The Procleix ArboPlex Assay was developed as an automated nucleic acid test capable of simultaneously identifying the presence of dengue, Chikungunya, Zika, and West Nile viruses in human plasma samples. This regulatory certification enabled the company to introduce the four-in-one assay to the European market, aiming to enhance the efficiency of blood screening processes and improve donor safety by streamlining the detection of these mosquito-borne pathogens.

Key Market Players

• Becton Dickinson & Co
• bioMérieux SA
• Abbott Laboratories Inc.
• Quidel Corporation
• OraSure Technologies, Inc.
• Hologic Inc.
• Cepheid
• QIAGEN N. V.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.

By Test Type	By End User	By Region
RT-PCR Test ELISA-Test	Hospitals Diagnostic Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Arbovirus Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Arbovirus Testing Market, By Test Type:

• RT-PCR Test
• ELISA-Test

• Arbovirus Testing Market, By End User:

• Hospitals
• Diagnostic Centers

• Arbovirus Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE